A key aim of systems biology is the reconstruction of molecular networks. We do not yet, however, have networks that integrate information from all datasets available for a particular clinical condition. This is in part due to the limited scalability, in terms of required computational time and power, of existing algorithms. Network reconstruction methods should also be scalable in the sense of allowing scientists from different backgrounds to efficiently integrate additional data. We present a network model of acute myeloid leukemia (AML). In the current version (AML 2.1), we have used gene expression data (both microarray and RNA-seq) from 5 different studies comprising a total of 771 AML samples and a protein–protein interactions dataset. Our scalable network reconstruction method is in part based on the well-known property of gene expression correlation among interacting molecules. The difficulty of distinguishing between direct and indirect interactions is addressed by optimizing the coefficient of variation of gene expression, using a validated gold-standard dataset of direct interactions. Computational time is much reduced compared to other network reconstruction methods. A key feature is the study of the reproducibility of interactions found in independent clinical datasets. An analysis of the most significant clusters, and of the network properties (intraset efficiency, degree, betweenness centrality, and PageRank) of common AML mutations demonstrated the biological significance of the network. A statistical analysis of the response of blast cells from 11 AML patients to a library of kinase inhibitors provided an experimental validation of the network. A combination of network and experimental data identified CDK1, CDK2, CDK4, and CDK6 and other kinases as potential therapeutic targets in AML.
Get full access to this article
View all access options for this article.
References
1.
BakerM.2012. Gene data to hit milestone. Nature, 487, 282–283.
2.
BarratA., BarthelemyM., Pastor-SatorrasR., and VespignaniA.2004. The architecture of complex weighted networks. Proc. Natl. Acad. Sci. USA, 101, 3747–3752.
3.
BarreB., and PerkinsN.D.2007. A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J., 26, 4841–4855.
4.
BassoK., MargolinA.A., StolovitzkyG., et al.2005. Reverse engineering of regulatory networks in human B cells. Nat. Genet. 37, 382–390.
5.
BrowerV.2014. Cell Cycle inhibitors make progress. J. Natl. Cancer Inst., 106, dju221.
6.
BrumfielG.2012. Higgs triumph opens up field of dreams. Nature, 487, 147–148.
7.
CahanP., LiH., MorrisS.A., et al.2014. CellNet: network biology applied to stem cell engineering. Cell, 158, 903–915.
8.
CasadevallA., and FangF.C.2010. Reproducible science. Infect. Immun., 78, 4972–4975.
9.
CsermelyP., KorcsmarosT., KissH.J., et al.2013. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol. Ther., 138, 333–408.
10.
Diaz-MoralliS., Tarrado-CastellarnauM., MirandaA., and CascanteM.2013. Targeting cell cycle regulation in cancer therapy. Pharmacol. Ther., 138, 255–271.
11.
Dos SantosC., McDonaldT., HoY.W., et al.2013. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood, 122, 1900–1913.
12.
Editorial. 2008. Community cleverness required. Nature, 455, 1.
13.
EppertK., TakenakaK., LechmanE.R., et al.2011. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med., 17, 1086–1093.
14.
FealaJ.D., CortesJ., DuxburyP.M., et al.2012. Statistical properties and robustness of biological controller-target networks. PLoS One, 7, e29374.
15.
FealaJ.D., CortesJ., DuxburyP.M., et al.2010. Systems approaches and algorithms for discovery of combinatorial therapies. WIREs Syst. Biol. Med., 181–193.
16.
FurlongL.I.2013. Human diseases through the lens of network biology. Trends Genet. 29, 150–159.
17.
Grosjean-RaillardJ., TaillerM., AdesL., et al.2009. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene, 28, 1099–1109.
18.
GuidanceF.D.2010. Adaptive design clinical trials for drugs and biologics. Biotechnol. Law Rep.197.
19.
HalevyA., NorvigP., and PereiraF.2009. The unreasonable effectiveness of data. Intell. Syst. IEEE, 24, 8–12.
20.
HauryA.C., MordeletF., Vera-LiconaP., and VertJ.P.2012. TIGRESS: Trustful Inference of Gene REgulation using Stability Selection. BMC Syst. Biol., 6, 145.
21.
HoffmanR., BenzE.J.Jr., SilbersteinL.E., et al.2012. Hematology: Basic Principles and Practice. Elsevier Health Sciences, New York, NY.
22.
Huang daW., ShermanB.T., and LempickiR.A.2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc., 4, 44–57.
23.
HughesP.J., MarcinkowskaE., GocekE., et al.2010. Vitamin D3-driven signals for myeloid cell differentiation—implications for differentiation therapy. Leuk. Res., 34, 553–565.
24.
Huynh-ThuV.A., IrrthumA., WehenkelL., and GeurtsP.2010. Inferring regulatory networks from expression data using tree-based methods. PLoS One, 5, e12776.
25.
IoannidisJ.P.2005. Why most published research findings are false. PLoS Med., 2, e124.
26.
KangY., HodgesA., OngE., et al.2014. Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias. PLoS One, 9, e102221.
27.
KeeganK., LiC., LiZ., et al.2014. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia. Mol. Cancer Ther., 13, 880–889.
28.
LapennaS., and GiordanoA.2009. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov., 8, 547–566.
29.
LawrenceM.S., StojanovP., MermelC.H., et al.2014. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505, 495–501.
30.
LeeE., JungH., RadivojacP., et al.2009. Analysis of AML genes in dysregulated molecular networks. BMC Bioinformatics, 10Suppl 9, S2.
31.
LefebvreC., RajbhandariP., AlvarezM.J., et al.2010. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol., 6, 377.
32.
LefebvreC., RieckhofG., and CalifanoA.2012. Reverse-engineering human regulatory networks. Wiley Interdiscip. Rev. Syst. Biol. Med., 4, 311–325.
33.
LingerR.M., KeatingA.K., EarpH.S., and GrahamD.K.2008. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res., 100, 35–83.
34.
MacraeT., SargeantT., LemieuxS., et al.2013. RNA-Seq reveals spliceosome and proteasome genes as most consistent transcripts in human cancer cells. PLoS One, 8, e72884.
35.
MalumbresM., and BarbacidM.2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer, 9, 153–166.
36.
MarbachD., CostelloJ.C., KuffnerR., et al.2012a. Wisdom of crowds for robust gene network inference. Nat. Methods, 9, 796–804.
37.
MarbachD., RoyS., AyF., et al.2012b. Predictive regulatory models in Drosophila melanogaster by integrative inference of transcriptional networks. Genome Res., 22, 1334–1349.
38.
MargolinA.A., and CalifanoA.2007. Theory and limitations of genetic network inference from microarray data. Ann. NY Acad. Sci., 1115, 51–72.
39.
Mayer-SchonbergerV., and CukierK.2013. Big Data: A Revolution That Will Transform How We Live, Work, and Think. Houghton Mifflin Harcourt, New York, NY.
40.
MetzelerK.H., HummelM., BloomfieldC.D., et al.2008. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood, 112, 4193–4201.
41.
MeyerP.E., LafitteF., and BontempiG.2008. minet: A R/Bioconductor package for inferring large transcriptional networks using mutual information. BMC Bioinformatics, 9, 461.
42.
MoonesingheR., KhouryM.J., and JanssensA.C.J.2007. Most published research findings are false, but a little replication goes a long way. PLoS Med., 4, e28.
43.
MorganM.A., DolpO., and ReuterC.W.2001. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood, 97, 1823–1834.
44.
NewmanM.2010. Networks: An Introduction. Oxford University Press, Oxford, UK.
45.
NowakD., StewartD., and KoefflerH.P.2009. Differentiation therapy of leukemia: 3 decades of development. Blood, 113, 3655–3665.
46.
OkamotoM., HayakawaF., MiyataY., et al.2007. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia, 21, 403–410.
47.
PathanN.I., GeahlenR.L., and HarrisonM.L.1996. The protein-tyrosine kinase Lck associates with and is phosphorylated by Cdc2. J. Biol. Chem., 271, 27517–27523.
48.
PlackeT., FaberK., NonamiA., et al.2014. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood, 124, 13–23.
49.
RobinsonL.J., XueJ., and CoreyS.J.2005. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp. Hematol., 33, 469–479.
50.
SchadtE.E., LindermanM.D., SorensonJ., et al.2010. Computational solutions to large-scale data management and analysis. Nat. Rev. Genet., 11, 647–657.
51.
SchaeferM.H., FontaineJ.F., VinayagamA., et al.2012. HIPPIE: Integrating protein interaction networks with experiment based quality scores. PLoS One, 7, e31826.
52.
SeniG., and ElderJ.F.2010. Ensemble methods in data mining: improving accuracy through combining predictions. Synthesis Lect. Data Mining Knowledge Discov., 2, 1–126.
53.
ShermanR.E., LiJ., ShapleyS., et al.2013. Expediting drug development—the FDA's new “breakthrough therapy” designation. N. Engl. J. Med., 369, 1877–1880.
54.
SzedlakA., PaternostroG., and PiermarocchiC.2014. Control of asymmetric Hopfield networks and application to cancer attractors. PLoS One, 9, e105842.
55.
The Cancer Genome Atlas RN. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074.
56.
ThieleI., SwainstonN., FlemingR.M., et al.2013. A community-driven global reconstruction of human metabolism. Nat. Biotechnol., 31, 419–425.
57.
TibesR., BogenbergerJ.M., ChaudhuriL., et al.2012. RNAi screening of the kinome with cytarabine in leukemias. Blood, 119, 2863–2872.
58.
TizianiS., KangY., HarjantoR., et al.2013. Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia. PLoS One, 8, e82859.
59.
TonelliG.2013. High statistics study of the higgs properties as a possible clue to new physics.
60.
TranT., OngE., HodgesA., et al.2014. Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression. BMC Syst. Biol., 8, 74.
61.
UssarS., and VossT.2004. MEK1 and MEK2, different regulators of the G1/S transition. J. Biol. Chem., 279, 43861–43869.
62.
ValkP.J., VerhaakR.G., BeijenM.A., et al.2004. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617–1628.
63.
VogelsteinB., PapadopoulosN., VelculescuV.E., et al.2013. Cancer genome landscapes. Science, 339, 1546–1558.
64.
WalsbyE., LazenbyM., PepperC., and BurnettA.K.2011. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia, 25, 411–419.
65.
WangL., WangJ., BlaserB.W., et al.2007. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood, 110, 2075–2083.
66.
WeberS.2004. The Success of Open Source. Harvard University Press, Cambridge, MA.
67.
WeinbergR.A.2014. Coming full circle-from endless complexity to simplicity and back again. Cell, 157, 267–271.
68.
WheelerD.A., and WangL.2013. From human genome to cancer genome: the first decade. Genome Res., 23, 1054–1062.
69.
WhitmanS.P., KohlschmidtJ., MaharryK., et al.2014. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia, 28, 1252–1258.
70.
WingenderE.2008. The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinform., 9, 326–332.
71.
WinterC., KristiansenG., KerstingS., et al.2012. Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput. Biol., 8, e1002511.
72.
YangX., LiuL., SternbergD., et al.2005. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res. 65, 7338–7347.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
